International News

Since 26 May 2021, the new and stricter legislation for the market authorization of medical devices in the EU, the Medical Device Regulation (MDR),…

In the festive setting of the event organised by the Chamber of Industry and Commerce of Central Switzerland (ihz), Geistlich CEO Ralf P. Halbach and…

Geistlich Pharma has been working successfully with Meta, the medical technology division of C.G.M. S.p.A., for many years. With the acquisition of…

Geistlich Pharma obtains 510(k) clearance from the US Food and Drug Administration (FDA) for its latest product Geistlich Nexo-Gide®. It will be…

Geistlich Pharma wins the Innovation Recognition Award for the medical device Geistlich Derma-Gide®. Launched on the US market in 2019, the product…

Five questions for Friedrich Buck, who is responsible for Geistlich's "Scientific Education" with his team. He himself is a dentist with many years of…

Geistlich Pharma's Surgery business unit becomes the exclusive distribution partner for the NUsurface® meniscus implant in Switzerland and enters into…

Last weekend Geistlich once again called for the "Geistlich Charity Walk & Run". The employees came in droves: Participants around the world ran for a…

This summer, three apprentices at Geistlich successfully obtained their Swiss Federal Certificate of Competence (EFZ). We are proud and congratulate…

Having started at Geistlich from the beginning of 2021, Dr. Ralf Halbach took the helm as CEO from July. We review his first few months in the company…

As of July 1, 2021, the management of Geistlich Pharma will be newly formed. Paul Note will hand over the controls to his successor Ralf Halbach. Rolf…

Seven questions about MEFISTO, a Horizon 2020 EU project in which Geistlich is the coordinator of the overall project as well as a scientific partner.…

As of today, Geistlich Biomaterials' "The New Daily Practice" website is live!

The new Geistlich podcast is here. It accompanies you on the journey to our in-house research & development. Immerse yourself in the world of…

After a global slump in sales due to the coronavirus pandemic, Geistlich Pharma rebounded quickly across the board from the middle of the year. The…

Out of the 6,000 people who participated in “Geistlich + YOU2”, 1,050 actively took part in the virtual hands-on workshop given by Prof. Dr. Ronald E.…

Geistlich Pharma has been granted Breakthrough Device Designation for Chondro-Gide® by the US Food and Drug Administration (FDA). Chondro-Gide® is a…

Over 6000 specialists in dentistry have benefited from the knowledge of top-class, international experts. The online congress focused on offering…

People from 100 nations will be attending this congress and you can be right at the heart of it too. Taking part in “Geistlich + YOU2” will allow you…

In January 2021, Ralf P. Halbach has taken up the position as designated CEO at Geistlich Pharma. As of July 1, 2021, he will officially take over…

After a long run of 3,988 kilometers, Geistlich Pharma’s annual donation found its destiny – Geistlich handed it over in São Paulo to the non-profit…